QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
- Written by PR Newswire
- STELFONTA (tigilanol tiglate injection) is now approved by the U.S. Food and Drug Administration's Center for Veterinary Medicine for the treatment of non-metastatic mast cell tumours (MCT) in dogs, making it the first pharmaceutical treatment available for all grades of canine non-metastatic MCT[1]
- FDA approval follows the early 2020 marketing...
Read more: QBiotics' STELFONTA® Receives FDA Approval for Canine Mast cell Tumours
